The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy

C. Zachariae; N.J. Mork; T. Reunala; H. Lorentzen; E. Falk; S.L. Karvonen; A. Johannesson; B. Clareus; L. Skov; G. Mork; S. Walker; S. Qvitzau

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy

C. Zachariae, N.J. Mork, T. Reunala, H. Lorentzen, E. Falk, S.L. Karvonen, A. Johannesson, B. Clareus, L. Skov, G. Mork, S. Walker, S. Qvitzau

104 Citations (Scopus)

Abstract

Many patients with moderate-to-severe plaque psoriasis do not respond adequately to methotrexate monotherapy. This pilot study, with a small patient population, was performed to evaluate the effectiveness and safety of etanercept and methotrexate combination in patients with plaque psoriasis and inadequate response to methotrexate. Outpatients with plaque psoriasis (Psoriasis Area and Severity Index >= 8 and/or body surface area > 10%), despite methotrexate treatment (>= 3 months; >= 7.5 mg/ week) were randomized to either etanercept with methotrexate tapered and discontinued (n = 28) or etanercept with continuous methotrexate (n = 31). Significantly more patients had a Physicians' Global Assessment of "clear"/"almost clear" in the combination group compared with etanercept/methotrexate taper (66.7 vs. 37.0%, respectively; p = 0.025). Adverse events were similar for both groups, with no cases of tuberculosis, malignancies or opportunistic infections reported. Addition of etanercept to methotrexate achieved significant improvement in psoriasis after 24 weeks
Udgivelsesdato: 2008

Original language	English
Journal	Acta Dermato Venereologica
Volume	88
Issue number	5
Pages (from-to)	495-501
Number of pages	6
ISSN	0001-5555
Publication status	Published - 2008

Cite this

@article{b9028e008bfe11de8bc9000ea68e967b,

title = "The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy",

abstract = "Many patients with moderate-to-severe plaque psoriasis do not respond adequately to methotrexate monotherapy. This pilot study, with a small patient population, was performed to evaluate the effectiveness and safety of etanercept and methotrexate combination in patients with plaque psoriasis and inadequate response to methotrexate. Outpatients with plaque psoriasis (Psoriasis Area and Severity Index >= 8 and/or body surface area > 10%), despite methotrexate treatment (>= 3 months; >= 7.5 mg/ week) were randomized to either etanercept with methotrexate tapered and discontinued (n = 28) or etanercept with continuous methotrexate (n = 31). Significantly more patients had a Physicians' Global Assessment of {"}clear{"}/{"}almost clear{"} in the combination group compared with etanercept/methotrexate taper (66.7 vs. 37.0%, respectively; p = 0.025). Adverse events were similar for both groups, with no cases of tuberculosis, malignancies or opportunistic infections reported. Addition of etanercept to methotrexate achieved significant improvement in psoriasis after 24 weeks Udgivelsesdato: 2008",

author = "C. Zachariae and N.J. Mork and T. Reunala and H. Lorentzen and E. Falk and S.L. Karvonen and A. Johannesson and B. Clareus and L. Skov and G. Mork and S. Walker and S. Qvitzau",

note = "Times Cited: 0ArticleEnglishZachariae, CCopenhagen Univ Hosp, Dept Dermatol, Niels Andersensvej 65, DK-2900 Hellerup, DenmarkCited References Count: 28353KVACTA DERMATO-VENEREOLOGICATRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDENUPPSALA",

year = "2008",

language = "English",

volume = "88",

pages = "495--501",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato - Venereologica",

number = "5",

}

TY - JOUR

T1 - The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy

AU - Zachariae, C.

AU - Mork, N.J.

AU - Reunala, T.

AU - Lorentzen, H.

AU - Falk, E.

AU - Karvonen, S.L.

AU - Johannesson, A.

AU - Clareus, B.

AU - Skov, L.

AU - Mork, G.

AU - Walker, S.

AU - Qvitzau, S.

N1 - Times Cited: 0ArticleEnglishZachariae, CCopenhagen Univ Hosp, Dept Dermatol, Niels Andersensvej 65, DK-2900 Hellerup, DenmarkCited References Count: 28353KVACTA DERMATO-VENEREOLOGICATRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDENUPPSALA

PY - 2008

Y1 - 2008

N2 - Many patients with moderate-to-severe plaque psoriasis do not respond adequately to methotrexate monotherapy. This pilot study, with a small patient population, was performed to evaluate the effectiveness and safety of etanercept and methotrexate combination in patients with plaque psoriasis and inadequate response to methotrexate. Outpatients with plaque psoriasis (Psoriasis Area and Severity Index >= 8 and/or body surface area > 10%), despite methotrexate treatment (>= 3 months; >= 7.5 mg/ week) were randomized to either etanercept with methotrexate tapered and discontinued (n = 28) or etanercept with continuous methotrexate (n = 31). Significantly more patients had a Physicians' Global Assessment of "clear"/"almost clear" in the combination group compared with etanercept/methotrexate taper (66.7 vs. 37.0%, respectively; p = 0.025). Adverse events were similar for both groups, with no cases of tuberculosis, malignancies or opportunistic infections reported. Addition of etanercept to methotrexate achieved significant improvement in psoriasis after 24 weeks Udgivelsesdato: 2008

AB - Many patients with moderate-to-severe plaque psoriasis do not respond adequately to methotrexate monotherapy. This pilot study, with a small patient population, was performed to evaluate the effectiveness and safety of etanercept and methotrexate combination in patients with plaque psoriasis and inadequate response to methotrexate. Outpatients with plaque psoriasis (Psoriasis Area and Severity Index >= 8 and/or body surface area > 10%), despite methotrexate treatment (>= 3 months; >= 7.5 mg/ week) were randomized to either etanercept with methotrexate tapered and discontinued (n = 28) or etanercept with continuous methotrexate (n = 31). Significantly more patients had a Physicians' Global Assessment of "clear"/"almost clear" in the combination group compared with etanercept/methotrexate taper (66.7 vs. 37.0%, respectively; p = 0.025). Adverse events were similar for both groups, with no cases of tuberculosis, malignancies or opportunistic infections reported. Addition of etanercept to methotrexate achieved significant improvement in psoriasis after 24 weeks Udgivelsesdato: 2008

M3 - Journal article

SN - 0001-5555

VL - 88

SP - 495

EP - 501

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 5

ER -